Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience (Nasdaq:YTEN) reported its financial results for Q4 and full-year 2022, highlighting strategic advancements in Camelina products aimed at biofuels, omega-3 oil, and bioplastics. The company ended 2022 with $4.3 million in unrestricted cash, down from $16 million in 2021, reflecting increased cash usage for operations, projected at $13-$14 million for 2023. Yield10 secured partnerships for Camelina feedstock oil and advanced herbicide-tolerant varieties, anticipating significant grower adoption. Despite these developments, the company faced a net loss of $13.6 million for the year, or $2.76 per share, compared to a loss of $11 million in 2021.
Yield10 Bioscience (Nasdaq: YTEN) announced they will report their fourth quarter and full year 2022 financial results on March 14, 2023. The management will host a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can call 1-877-709-8150 in the U.S. or +1-201-689-8354 internationally. A live webcast will also be available on their website. The replay of the call will be accessible three hours post-call until March 28, 2023. Yield10 focuses on developing improved Camelina varieties and has a goal to establish a high-value seed products business for the agriculture and food industry.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) has signed a Memorandum of Understanding with American Airlines (NASDAQ: AAL) to develop Camelina as a low-carbon feedstock for sustainable aviation fuel (SAF). This collaboration aims to create a supply chain for Camelina oil-based SAF, potentially securing offtake agreements for its commercial use. The partnership also seeks government grants to support the necessary infrastructure. Camelina is viewed as a vital crop for reducing carbon emissions due to its environmental benefits, such as erosion control and soil moisture maintenance.
Yield10 Bioscience (Nasdaq:YTEN) announced significant advancements in developing herbicide tolerant Camelina crops. Field trials in the Southern U.S. confirmed that their E3902 HT spring Camelina lines are tolerant to commonly used broadleaf herbicides and grassy weed control products. The company aims to increase grower adoption of Camelina for biofuel feedstock. Yield10 plans further seed scale-up, field tests, and regulatory advancements in 2023. A request for Regulatory Status Review under the SECURE Rule was submitted to USDA-APHIS, with an expected agency response pending. The success of these developments is crucial for establishing Camelina in the North American agricultural market.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
